Inderal XL (Propranolol HCl) Patent Expiration, LOE Window & CMS Spending
Inderal XL (Propranolol HCl) by Ani: Off-Patent Genericized (AB Competition), 19 AB generics, $1.7M 2024 CMS Part D & Medicaid spend, and $2,543 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ani |
| FDA Application & Pathway | N018553 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 19 |
| 2024 CMS Total Public Spend | $1.7M |
| 2024 Medicare Part D Spend | $1.1M |
| 2024 Medicaid Spend | $607K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($2,543 intro WAC) |